Posted by Michael Wonder on 18 Aug 2016
Cancer drug appraisal needs to be reviewed
18 August 2016 - ABPI Executive pens letter to The Guardian.
Richard Torbett claims the UK pharmaceutical industry is about doing everything possible to ensure cancer patients get access to much needed medicines, yet it fails to offer a rounded perspective on affordability and drugs availability in the NHS.
Torbett says the industry is acutely aware that our health service has limited money to treat millions of patients with wide-ranging medical conditions, but continuing to cut prices may not be sustainable into the future and is no silver bullet.
